Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO4010 with Nivolumab and/or Bevacizumab in Metastatic Colorectal Cancer
NCT05589597Phase 2Terminated
- Sponsor
- Enterome
- Start
- Jun 2023
- Primary completion
- May 2025
- Modality
- Peptides, Peptide-based Cancer Vaccines, Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of EO4010 in colorectal cancer (CRC) (3 cohorts), sponsored by Enterome. Primary endpoint: Safety and Tolerability of EO4010 in Combination With Nivolumab and/or Bevacizumab at 24 months. Started Jun 2023; status: terminated.
02
Drugs
EO4010
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05589597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05589597.